bLAC - A Phase II Double-Blind, Placebo Controlled, Clinical Proof of Concept Trial of the Efficacy of 8 Weeks Treatment of Cutaneous Warts With bLAC in Immune Suppressed, Kidney Transplanted Patients

As many as 85 % of renal transplant patients may suffer from viral warts with a high degree of treatment resistance. Promising results of hLAC (human lactalbumin complex with lipid) point to a beneficial effect without noticeable side effects of bLAC (bovine lactalbumin complex with lipid). The aim of first clinical trial with bLAC is to show proof of concept in treatment of cutaneous wart lesions on hands and/or feet after local administration of bLAC in two dose groups to immune suppressed, kidney transplanted patients.

Start Date01 Mar 2008

Sponsor / Collaborator

Azanta Danmark A/S

100 Clinical Results associated with Bovine lactalbumin complex with lipid(NatImmune A/S)

100 Translational Medicine associated with Bovine lactalbumin complex with lipid(NatImmune A/S)

100 Patents (Medical) associated with Bovine lactalbumin complex with lipid(NatImmune A/S)

Literatures (Medical) associated with Bovine lactalbumin complex with lipid(NatImmune A/S)

01 Jun 2024·International Journal of Biological Macromolecules

Direct conversion of lignin-rich black liquor to activated carbon for supercapacitor electrodes

Article

Author: Yadav, Kushagra ; Gupta, Ashish ; Dhakate, S R ; Saharan, Pinky ; Singh, Mandeep ; Jain, Karishma

The escalating industrialization trend underscores the imperative for sustainable waste management practices. The present investigation explores a sustainable methodology for managing the waste generated from the kraft process by directly converting it into activated carbon (BLAC) through a cost-effective hydrothermal-assisted activation method. The research involved a comparative analysis of BLAC with acid-washed black liquor lignin-derived activated carbon (ABLAC) and commercial lignin-derived activated carbon (SALAC). The analysis revealed that BLAC possesses a well-developed micro and mesoporous structure, yielding a significantly higher surface area of 2277.2 m²/g as compared to ABLAC (1260 m²/g) and SALAC (1558.4 m²/g). The presence of inherent alkali in the black liquor is the main factor influencing the surface area of the BLAC. Furthermore, it demonstrated impressive electrochemical performance, showing a specific capacitance value of 871.4 F/g at 1 A/g current density, positioning it as a formidable electrode material for supercapacitor applications. The proposed direct conversion strategy will eliminate the need for high-temperature pre‑carbonization and additional lignin extraction, reducing chemical usage and presenting a greener approach.

01 Nov 2022·Biosensors and Bioelectronics

High-throughput fluorescent screening of β-lactamase inhibitors to improve antibiotic treatment strategies for tuberculosis

Article

Author: Ma, Xiaochi ; Cui, Jingnan ; Wang, Jiayue ; He, Shengui ; Wang, Chao ; Tian, Xiangge ; James, Tony D ; Yan, Fei ; Han, Xiuyan ; Feng, Lei

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb), which is a major threat to global public health. Currently, β-lactam antibiotics are rarely used in the treatment of TB, since Mtb naturally expresses β-lactamase (Blac) which renders Mtb resistant to such antibiotics due to β-lactam cleavage. Fortunately, antibiotic resistance can be overcome when β-lactam antibiotics are combined with a Blac inhibitor. With the current research, a near-infrared fluorescent probe LXMB was developed for the real-time detection and imaging of endogenous Blac activity in Mtb. Furthermore, a high-throughput screening platform was established using LXMB to screen Blac inhibitors from herbal medicines. Guided by the visual bioassay, Tannic acid was isolated from Galla Chinensis as a potential Blac inhibitor and was further evaluated in combination with several β-lactam antibiotics which resulted in an enhanced inhibitory effect toward M. tuberculosis H37Ra. Finally, LXMB was used to label live M. tuberculosis H37Ra phagocytosed within macrophages. Consequently, LXMB was a useful fluorescent tool to explore the mechanism of drug resistance based on Blac and can assist in the development of new tuberculosis treatments.

01 Sep 2015·Antimicrobial Agents and ChemotherapyQ2 · MEDICINE

Hydrolysis of Clavulanate by Mycobacterium tuberculosis β-Lactamase BlaC Harboring a Canonical SDN Motif

Q2 · MEDICINE

Article

Author: Barros, David ; Li de la Sierra-Gallay, Inès ; Dubée, Vincent ; van Tilbeurgh, Herman ; Arthur, Michel ; Hugonnet, Jean-Emmanuel ; Soroka, Daria ; Mainardi, Jean-Luc ; Compain, Fabrice ; Ballell, Lluis ; Triboulet, Sébastien

ABSTRACT Combinations of β-lactams with clavulanate are currently being investigated for tuberculosis treatment. Since Mycobacterium tuberculosis produces a broad spectrum β-lactamase, BlaC, the success of this approach could be compromised by the emergence of clavulanate-resistant variants, as observed for inhibitor-resistant TEM variants in enterobacteria. Previous analyses based on site-directed mutagenesis of BlaC have led to the conclusion that this risk was limited. Here, we used a different approach based on determination of the crystal structure of β-lactamase Bla MAb of Mycobacterium abscessus , which efficiently hydrolyzes clavulanate. Comparison of Bla MAb and BlaC allowed for structure-assisted site-directed mutagenesis of BlaC and identification of the G 132 N substitution that was sufficient to switch the interaction of BlaC with clavulanate from irreversible inactivation to efficient hydrolysis. The substitution, which restored the canonical SDN motif (SDG→SDN), allowed for efficient hydrolysis of clavulanate, with a more than 10 4 -fold increase in kcat (0.41 s −1 ), without affecting the hydrolysis of other β-lactams. Mass spectrometry revealed that acylation of BlaC and of its G 132 N variant by clavulanate follows similar paths, involving sequential formation of two acylenzymes. Decarboxylation of the first acylenzyme results in a stable secondary acylenzyme in BlaC, whereas hydrolysis occurs in the G 132 N variant. The SDN/SDG polymorphism defines two mycobacterial lineages comprising rapidly and slowly growing species, respectively. Together, these results suggest that the efficacy of β-lactam–clavulanate combinations may be limited by the emergence of resistance. β-Lactams active without clavulanate, such as faropenem, should be prioritized for the development of new therapies.

100 Deals associated with Bovine lactalbumin complex with lipid(NatImmune A/S)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Warts	Phase 2	DK	Azanta Danmark A/S	01 Mar 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Bovine lactalbumin complex with lipid(NatImmune A/S)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation